Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peijia MedicalPEJMF 80 3-Year EBITDA Growth Rate is 30.10% as of Dec. 2025, which is at its 10-year median of 30.10. GuruFocus rates PEJMF with a GF Score™ of 80/100 and a GF Value™ of $2.13. The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Peijia Medical ranks better than 77.1% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 30.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 44.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Peijia Medical was 52.40% per year. The lowest was -91.00% per year. And the median was 30.10% per year.
Peijia Medical (OTCPK:PEJMF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Peijia Medical 3-Year EBITDA Growth Rate Related Terms
PEJMF vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Peijia Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peijia Medical 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Peijia Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Peijia Medical's 3-Year EBITDA Growth Rate falls into.
Peijia Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 30.10% mean?
Peijia Medical (PEJMF) has a 3-Year EBITDA Growth Rate of 30.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Peijia Medical and its competitors. This is near median its historical median of 30.10. According to the industry distribution chart, Peijia Medical ranks #158 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 22.9%.
Is Peijia Medical's 3-Year EBITDA Growth Rate too high?
Peijia Medical's current 3-Year EBITDA Growth Rate of 30.10% is near median its 10-year median of 30.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.35. Peijia Medical's value of 30.10% is 260.5% above this industry median. Based on the distribution chart, Peijia Medical ranks #158 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Peijia Medical has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Peijia Medical's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Peijia Medical ranks #158 out of 690 companies for 3-Year EBITDA Growth Rate. This places Peijia Medical in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.35. Peijia Medical's value of 30.10% is 260.5% above this benchmark. While the company's 10-year median is 30.10 vs. the industry median of 8.35, Peijia Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.35, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peijia Medical's current 3-Year EBITDA Growth Rate of 30.10% is 260.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Peijia Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peijia Medical's current 3-Year EBITDA Growth Rate is 30.10%, which is near median its own 10-year median of 30.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peijia Medical stock overvalued right now?
Peijia Medical (PEJMF) has a current 3-Year EBITDA Growth Rate of 30.10%. The stock's GF Value™ is $2.13, compared to a current price of $1.39 — trading 34.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 30.10%, which is near median its 10-year median of 30.10 and 260.5% above the Medical Devices & Instruments industry median of 8.35. Peijia Medical's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Peijia Medical (PEJMF), the current 3-Year EBITDA Growth Rate is 30.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peijia Medical (PEJMF) Overvalued in 2026?
Based on GuruFocus' analysis, Peijia Medical stock appears to be undervalued.
The current stock price of $1.39 is trading 34.9% below its estimated GF Value™ of $2.13.
Key valuation signals for PEJMF:
3-Year EBITDA Growth Rate: 30.10% (near median its 10-year median of 30.10)
GF Value™: $2.13 vs. price of $1.39 (34.9% below fair value)
Industry Position: 260.5% above the Medical Devices & Instruments median (#158 of 690)
No single metric tells the full story. See the PEJMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peijia Medical Ltdis a provider of inventive medical products and solutions. It focuses on the high-growth interventional procedural medical device market in China. Its products and product candidates target large, fast-growing and under-penetrated markets with high entry barriers, including the transcatheter valve therapeutic medical device market and the neurointerventional procedural medical device market. The Company's product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates spanning three key business segments: Transcatheter Valve Therapeutic Business, Future Technology Business and Neurointerventional Business.
80GF Score
Get the complete analysis for PEJMF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEJMF has been successfully added to your 
